The Medical Letter on Drugs and Therapeutics
Ceritinib (Zykadia) for Non-Small Cell Lung Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Ceritinib (Zykadia – Novartis), an oral tyrosine kinase inhibitor, has received accelerated approval from the FDA for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib (Xalkori). It is the second tyrosine kinase inhibitor to be approved for ALK-positive metastatic NSCLC; crizotinib was the first.1 Translocations of the ALK gene are found in about 5% of lung cancers2; they occur predominantly in nonsmokers with adenocarcinoma.

MECHANISM OF ACTION — Translocations of ALK, a receptor tyrosine kinase, result in expression of oncogenic fusion proteins, which increase cell proliferation. Ceritinib inhibits ALK and other receptor tyrosine kinases.

CLINICAL STUDIES — A ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Ceritinib (Zykadia) for Non-Small Cell Lung Cancer
Article code: 1447d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian